- Home
- EDRY vs ASBP Comparison
EDRY vs ASBP Comparison
Compare EDRY & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDRY
- ASBP
- Stock Information
- Founded
- EDRY 2018
- ASBP 2021
- Country
- EDRY Greece
- ASBP United States
- Employees
- EDRY N/A
- ASBP N/A
- Industry
- EDRY Marine Transportation
- ASBP Biotechnology: Pharmaceutical Preparations
- Sector
- EDRY Consumer Discretionary
- ASBP Health Care
- Exchange
- EDRY Nasdaq
- ASBP Nasdaq
- Market Cap
- EDRY 27.3M
- ASBP 26.6M
- IPO Year
- EDRY N/A
- ASBP N/A
- Fundamental
- Price
- EDRY $12.20
- ASBP $0.45
- Analyst Decision
- EDRY
- ASBP
- Analyst Count
- EDRY 0
- ASBP 0
- Target Price
- EDRY N/A
- ASBP N/A
- AVG Volume (30 Days)
- EDRY 2.2K
- ASBP 5.2M
- Earning Date
- EDRY 08-11-2025
- ASBP 08-13-2025
- Dividend Yield
- EDRY N/A
- ASBP N/A
- EPS Growth
- EDRY N/A
- ASBP N/A
- EPS
- EDRY N/A
- ASBP N/A
- Revenue
- EDRY $49,707,775.00
- ASBP N/A
- Revenue This Year
- EDRY N/A
- ASBP N/A
- Revenue Next Year
- EDRY $28.45
- ASBP N/A
- P/E Ratio
- EDRY N/A
- ASBP N/A
- Revenue Growth
- EDRY N/A
- ASBP N/A
- 52 Week Low
- EDRY $7.60
- ASBP $0.22
- 52 Week High
- EDRY $20.79
- ASBP $15.80
- Technical
- Relative Strength Index (RSI)
- EDRY 67.96
- ASBP 50.21
- Support Level
- EDRY $10.70
- ASBP N/A
- Resistance Level
- EDRY $12.48
- ASBP $0.47
- Average True Range (ATR)
- EDRY 0.20
- ASBP 0.05
- MACD
- EDRY 0.14
- ASBP -0.03
- Stochastic Oscillator
- EDRY 84.96
- ASBP 74.84
About EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.
About ASBP Aspire Biopharma Holdings Inc. Common Stock
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.